News
科思
/
/
/
The randomized controlled trial of 3D printing fully degradable coronary drug-eluting stent system, an innovative device independently developed by Beijing Amet, successfully completed the enrollment of the first three subjects

The randomized controlled trial of 3D printing fully degradable coronary drug-eluting stent system, an innovative device independently developed by Beijing Amet, successfully completed the enrollment of the first three subjects

  • Categories:Company News
  • Author:
  • Origin:
  • Time of issue:2021-07-13 09:11
  • Views:

(Summary description)Recently, a randomized controlled clinical trial of the innovative medical device "3D printing fully degradable coronary drug-eluting stent system (trade name: AMSorbTM)" independently developed by Beijing Amat Medical Devices Co., Ltd. was conducted in Beijing affiliated to Capital Medical University. Anzhen Hospital successfully completed the enrollment of the first three subjects (including two in the experimental group and one in the control group). All three subjects were in good postoperative condition and have been discharged from the hospital.

The randomized controlled trial of 3D printing fully degradable coronary drug-eluting stent system, an innovative device independently developed by Beijing Amet, successfully completed the enrollment of the first three subjects

(Summary description)Recently, a randomized controlled clinical trial of the innovative medical device "3D printing fully degradable coronary drug-eluting stent system (trade name: AMSorbTM)" independently developed by Beijing Amat Medical Devices Co., Ltd. was conducted in Beijing affiliated to Capital Medical University. Anzhen Hospital successfully completed the enrollment of the first three subjects (including two in the experimental group and one in the control group). All three subjects were in good postoperative condition and have been discharged from the hospital.

  • Categories:Company News
  • Author:
  • Origin:
  • Time of issue:2021-07-13 09:11
  • Views:
Information

Recently, a randomized controlled clinical trial of the innovative medical device "3D printing fully degradable coronary drug-eluting stent system (trade name: AMSorbTM)" independently developed by Beijing Amat Medical Devices Co., Ltd. was conducted in Beijing affiliated to Capital Medical University. Anzhen Hospital successfully completed the enrollment of the first three subjects (including two in the experimental group and one in the control group). All three subjects were in good postoperative condition and have been discharged from the hospital.

In the two experimental groups, one case was implanted with a 3.0 × 23mm Ammet AMSorbTM stent in the subject's right coronary artery lesion; the other case was implanted in the subject's left circumflex artery lesion with a size of 3.0 mm. One Amate AMSorbTM stent with a size of 23mm, the interventional treatment of target lesions was successful, and the results after stent implantation were satisfactory.

"Multi-center, prospective clinical registration trial of fully degradable coronary drug-eluting stent system (trade name: AMSorbTM)" by Professor Huo Yong of Peking University First Hospital as the principal investigator, and Professor Zhou Yujie of Beijing Anzhen Hospital as the joint researcher The principal investigator, the small sample first-in-man trial (FIM, First in Man) in the registration trial has successfully completed the enrollment of all 30 subjects on November 19, 2019, and the follow-up of the FIM trial is ongoing, based on The existing follow-up data fully confirmed the good safety of the Amater AMSorbTM stent.

The successful launch of the randomized controlled clinical trial of the 3D printed fully degradable coronary drug-eluting stent system (trade name: Amater AMSorbTM) marks a big step forward in the clinical registration trial process of Amater AMSorbTM, and also provides a solid foundation for the follow-up Amater AMSorbTM clinical registration trial. The registration forensics of AMSorbTM stents laid the foundation.

PeriSorb® fully degradable peripheral vascular stent completes the first FIM trial enrollment
2021 12-25

PeriSorb® fully degradable peripheral vascular stent completes the first FIM trial enrollment

This is the world's first 3D printed fully degradable peripheral stent implanted in the human body, marking that my country's 3D printing fully degradable peripheral stent with completely independent intellectual property rights has taken the lead in entering the clinical trial stage, and it also marks that my country's 3D printing technology has advanced to the world's leading level. A big step.
Beijing adds 1,150 municipal-level "specialized, special and new" small and medium-sized enterprises
2021 12-03

Beijing adds 1,150 municipal-level "specialized, special and new" small and medium-sized enterprises

On December 1, the Beijing Economic and Information Bureau announced the list of the second to seventh batch of "specialized, special and new" small and medium-sized enterprises in Beijing in 2021. The list includes 1,150 small and medium-sized enterprises including Labtech, Digital Video, Geling Shentong, Moji Fengyun Technology, etc.
Beijing Amet was recognized as a "specialized, special and new" enterprise
2021 12-02

Beijing Amet was recognized as a "specialized, special and new" enterprise

On December 1, 2021, the Beijing Municipal Bureau of Economy and Information issued an announcement on the seventh batch of "specialized, refined, and new" small and medium-sized enterprises in 2021. The announcement announced that Beijing Amet Medical Equipment Co., Ltd. was recognized as a "specialized, refined and new" enterprise. This event marks that Amet, as an innovative enterprise, has reached a high level in terms of scientific research strength, technical level and influence, and has been recognized by the competent government departments.

Company Information

Beijing Advanced Medical Technologies,Ltd.Inc.

Contact Us

Address: Building 11, Zhongguancun Medical Equipment Park, No. 26, Yongwang West Road, Daxing District, Beijing

Tel:010-6297-7955           E-Mail:amt@ametcorp.com